MAP2K7 and breast cancer: The researchers then used the PPARγ agonist rosiglitazone (an anti-diabetic drug) in combination with the MEK inhibitor trametinib in a mouse breast cancer model and achieved differentiation of the breast cancer cells into adipocytes after EMT [12].